We mine massive multi-dimensional datasets to identify targetable nuances in the genetic code unique to different cell types. Malignant vs non-maglinant. Immune cells vs liver cells.
We insert these signatures into the designer mRNA to target specific cells. Hyperselective translation activates malignant cells to make cancer-fighting proteins. Other cells can be activated to make health-promoting ones.
We control the engineered mRNA’s journey into specific cells within target tissue using proprietary and versatile LNPs. By evading default accumulation in the liver, we can reach diverse tissues, such as tumor, spleen, and bone marrow.